Attention deficit hyperactivity disorder (ADHD) is among the most frequently reported coexisting psychiatric conditions in children with encopresis. Some case reports state that atomoxetine-a selective presynaptic norepinephrine reuptake inhibitor-approved for treatment of ADHD is also effective in the treatment of coexisting encopresis. Contrasting those reports, here we present a case diagnosed with ADHD and secondary encopresis without constipation whose encopretic symptoms increased after atomoxetine treatment and discuss possible mechanisms.
CASE
An 11-year-old boy was referred to our clinic with complaints of "hyperactivity, restlessness, impulsivity, short temper, behavioral problems, academic failure, encopresis (weekly), becoming bored quickly, and short attention span." Medical history including developmental milestones was normal and family history revealed no psychopathology. Reports from teachers, parents, and mental status examination all showed reduced attention span, hyperactivity, and impulsivity, all of which were inappropriate for developmental level and led to dysfunction. Encopresis reported to start after toilet training and continued at a stable rate of once/ week. No relationship with dietary factors could be ascertained. Intelligence was within normal limits according to clinical examination and Wechsler Intelligence Scale for Children-Revised. Pediatric consultation revealed neither a medical etiology nor constipation. Accordingly, he was diagnosed with ADHD-Combined Presentation and Encopresis (without constipation and over-flow) according to the American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria. Osmotic-controlled release oral delivery system (OROS) methylphenidate 27 mg/d and risperidone 1 mg/d were initiated for his symptoms, and parents were informed of behavioral methods to control encopresis. Evaluation at the second month of treatment revealed treatment response for ADHD symptoms but increased frequency of encopresis (4-5/day) despite behavioral interventions. Reconsultation from pediatrics demonstrated no pathology. Due to reports of increased encopresis and/or enuresis with risperidone 6, 7 ; risperidone was stopped, and OROS MPH was titrated to 36 mg/d. 8, 9 Behavioral intervention was continued for encopretic symptoms.
During monthly follow-up, ADHD symptoms remained in partial remission whereas encopresis did not change, and enuresis was added as a new symptom at the third month. OROS methylphenidate was gradually tapered, whereas atomoxetine 18 mg/d was initiated along with aripiprazole 2.5 mg/d at the sixth month. Atomoxetine was titrated up to 40 mg/d in a 3-week period. The parents reported 80.0% improvement in ADHD symptoms, whereas enuresis remitted fully at the eighth month. However, encopretic symptoms increased further along with atomoxetine titration and occurred daily (approximately 10/day). Therefore, atomoxetine dose was decreased to 18 mg/d, whereas aripiprazole was continued at the same dose. At the ninth and 10th month follow-ups, frequency of encopresis decreased gradually and was observed only a few times per week at the last evaluation while using atomoxetine 18 mg/d along with aripiprazole 2.5 mg/d.
DISCUSSION
Here, we report a complex case of ADHD and primary encopresis whose encopretic symptoms increased after initiation of stimulant treatment along with risperidone. Increased dose of stimulants and cessation of risperidone did not help in reducing encopretic symptoms, and the patient also developed de novo enuresis. Initiation of atomoxetine along with aripiprazole helped to control ADHD and enuresis, whereas encopresis increased in a dose-dependent fashion. Tapering the dose of atomoxetine and continuing treatment with aripiprazole helped control all of the patients symptoms (including those of ADHD, enuresis, and encopresis, at last).
Encopresis is defined as the repeated passage of feces into inappropriate places (ie, clothing, and so on) whether involuntary or intentional. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria describe 2 subtypes as "with constipation and overflow incontinence" and "without constipation and overflow incontinence." When the history and examination results of our patient were evaluated, he was judged to fulfill criteria for primary encopresis (without constipation and overflow) albeit his symptoms increased dramatically with treatments for ADHD. This observation was unexpected due to frequent reports of beneficial effects of agents used to control ADHD (both stimulants and atomoxetine) on encopresis concomitant with ADHD. 5, [7] [8] [9] [10] [11] [12] Hergüner and Hergüner reported 2 patients, 8 and 10 years old, respectively, diagnosed with ADHD and encopresis with constipation and overflow incontinence. They reported symptomatic improvement in both cases with atomoxetine. Türkoğlu et al presented 4 children with encopresis-2 of them diagnosed with coexisting ADHD-who displayed resolution of encopretic symptoms with atomoxetine treatment, regardless of the type of encopresis (primary/secondary or retentive/nonretentive types). They suggested that the antiencopretic effects of atomoxetine or methlyphenidate may be related to direct impact on executive functioning, self-organizing skills, and impulse control which enabled children to recognize and respond to internal cues to defecate. 10 Some of the authors posited that the effects of ADHD drugs on encopresis may be secondary to the resolution of child-parent relationship conflicts and poor social and academic functioning. 11 Yücel et al discussed the possible effective mechanism of atomoxetine on encopresis in a report and suggested that it may help encopresis via increased noradrenaline levels and therefore sympathetic activity in GIS. In another report, Akça and Yılmaz presented a case diagnosed with secondary encopresis and ADHD, whose ADHD symptoms remitted with atomoxetine without changing encopresis. They reported that their patient's encopretic symptoms remitted with methylphenidate. The authors posited that the anti-encopretic effects of stimulants may be related to their direct peripheral effects on GIS motility rather than effects on executive functioning, self-organizing skills or impulse control (ie, via D1 and D2 receptors). 13 The regulation of bowel movements involves complex physiological processes, including long-and short-reflexes, peptides and neurotransmitters. 14 There are also individual variations in both tonic and phasic responses of the autonomic nervous system which is involved in continence observable from infancy. 15 The complex and variable presentation of encopresis symptoms in our patient along with dissociation of treatment response of ADHD symptoms and those of encopresis argue against a relationship between bowel control and executive functions. 12 Risperidone which along with OROS methylphenidate increased encopresis in our patient binds to D2, 5HT2A, alpha 1 and 2 and H1 receptors. 16 D2 is also known to be involved in gastric and intestinal motility and MPH increases DA levels in GIS. 13 Therefore, we posit that D2 blockage superimposed on a chronically low tonic and high phasic tonus of the ANS may have increased encopresis in our patient. The cessation of risperidone as well as OROS methylphenidate may have changed the D2 occupancy, however, addition of aripiprazole may have stabilized DA functioning in the GIS at a low level, while elevation of NE via atomoxetine may have affected tonic and phasic activity of the ANS; increasing encopresis further. Reduction of atomoxetine dosage while continuing aripiprazole may have normalized the ANS activity without changing D2 occupancy, which may have helped reduce encopresis.
